Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business context and reporting period
Arcturus Therapeutics Holdings Inc. reported a material collaboration involving its wholly owned subsidiary, Arcturus Therapeutics, Inc. The definitive agreements were entered into on July 29, 2021 and became effective July 30, 2021. The filing was signed on August 3, 2021.
Material definitive agreements
Arcturus entered into a Technology License and Technical Support Agreement and a Framework Drug Substance Supply Agreement with Vinbiocare Biotechnology Joint Stock Company of Vietnam. The collaboration is intended to establish a Vietnamese manufacturing facility for Arcturus’s investigational COVID-19 vaccines, initially ARCT-021 and ARCT-154, for sale and use within Vietnam.
- Vinbiocare will build the facility in consultation with Arcturus.
- Arcturus granted Vinbiocare an exclusive license to manufacture final vaccine drug product in Vietnam solely for distribution within Vietnam.
- The technology transfer excludes manufacturing of mRNA drug substance and Arcturus’s proprietary LUNAR platform lipids.
- Arcturus will supply mRNA drug substance and proprietary lipids; Vinbiocare will procure other raw materials and inputs.
- Vinbiocare must pay a non-refundable upfront fee, reimburse technology-transfer costs, and pay royalties on vaccine doses produced at the facility.
- Arcturus will control vaccine development in Vietnam unless otherwise agreed, while Vinbiocare will handle commercialization in Vietnam.
Financial metrics, liquidity, and other key data
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, upfront-payment amount, royalty rate, supply pricing, or other quantitative financial information.
Outlook, risks, contingencies, and unusual items
- The license is scheduled to expire on December 31, 2032, unless terminated earlier.
- Arcturus may terminate under specified circumstances, including termination of the Supply Agreement, failure by Vinbiocare to make a commercial vaccine dose in Vietnam by December 31, 2023 following regulatory approval, or Arcturus’s decision to cease global manufacture, development, or commercialization of the vaccines.
- Vinbiocare may terminate the license for convenience; either party may terminate either agreement for an uncured material breach.
- Vinbiocare’s obligations under both agreements are guaranteed by its parent company.
- The agreements concern investigational vaccines and remain subject to regulatory approval, successful development, facility construction, technology transfer, manufacturing execution, and commercialization.
- The filing does not provide a specific development, approval, construction, or commercial-launch timetable beyond the December 31, 2023 commercial-dose condition.
Most important facts to verify
- Amounts and payment timing for the non-refundable upfront fee, technology-transfer costs, royalties, and mRNA drug-substance sales.
- Regulatory status and clinical progress of ARCT-021 and ARCT-154.
- Facility construction progress, manufacturing readiness, and compliance with Vietnamese regulatory requirements.
- Whether the required commercial dose was produced by December 31, 2023 or whether the license was terminated.
- The complete License Agreement and Supply Agreement exhibits, which the filing states would be included in the company’s Form 10-Q for the quarter ended June 30, 2021.